Natco Pharma receives favourable judgement, FMC appeal dismissed

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced that Double Bench of the Hon'ble High Court of Delhi has dismissed an appeal filed by FMC Corporation, FMC Singapore and FMC India and has upheld prima facie the Judgement of the Hon'ble Single Judge that the Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 578.75 as compared to the previous close of Rs. 582.80. The total number of shares traded during the day was 17812 in over 1485 trades.

The stock hit an intraday high of Rs. 586.20 and intraday low of 576.85. The net turnover during the day was Rs. 10328296.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 FavourableJudgement FMCAppeal